Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nucleoside-Sparing Combination Therapy With Lopinavir/Ritonavir (LPV/r) + Raltegravir (RAL) vs. Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Patients

NCT00752856 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.

NCT NCT00752856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00752856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nucleoside-Sparing Combination Therapy With Lopinavir/Ritonavir (LPV/r) + Raltegravir (RAL) vs. Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Patients
Lead sponsor
University of California, San Diego
Phase
Phase 2
Overall status
Completed
Start date
August 26, 2008
Completion date
February 11, 2014
Enrollment
51 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections